Knowledge and expertise
in the field of Kinase inhibitors

  • Libraries designed as ATP-competitive kinase inhibitors (both general new kinase scaffolds and novel focused compounds)
  • The libraries contained >20 novel scaffolds which were synthesised at a CRO. Screening of some representative compounds has identified novel hits with IC50s well below 1µM
  • Succesfull hit identification for novel target (STE family)
  • Innovative Type II kinase inhibitor library designed for a specific kinase target
  • Running 2 different kinase projects through several optimization cycles improving the activity/selectivity profiles, optimizing pharmacokinetic properties and solving identified issues
  • One compound delivered at IND stage (ROCK), one at EDC stage (PKC)

Who are we?


Discover Asclepia
Let us help you to grow your business!


T:  +32 474 48 71 50